

Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's other reports filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions identify forward-looking statements.

Section 1 - Registrant's Business and Operations

Item 1.01 - Entry Into a Material Definitive Agreement.

On October 22, 2010, we extended the term of our operating lease at 1301 Harbor Bay Parkway, Alameda, California. The new term is from December 1, 2010 until February 29, 2016. We increased the amount of laboratory and office space from approximately 11,000 square feet to approximately 17,000 square feet. Base rent is \$27,086 per month. Base rent will increase by three percent each year. We will receive two months of free rent at the beginning of the new lease term. In addition to the base rent, we pay a pro rata share of real property taxes and certain costs associated to the operation and maintenance of the building in which the leased premises are located.

The lease extension also contains an option to extend the lease for one additional term of five years, with the rent to be determined at the time of the extension based on the prevailing market rate for comparable facilities. We also obtained a right of first refusal on approximately 10,000 square feet of shell space that is contiguous to our current space.

The landlord, SKS Harbor Bay Associates, LLC, is providing a tenant improvement allowance of \$16 per square foot (\$270,864) which we will use to improve the GMP features of the leased space. The landlord is also replacing certain laboratory air handling equipment at their cost.

Section 9 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
-----------------------	--------------------

99.1	Press Release Dated October 26, 2010
------	--------------------------------------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOTIME, INC.

Date: October 26, 2010 By: /s/ Robert W. Peabody
Senior Vice President, Chief Operating
Officer and Chief Financial Officer

Exhibit Number Description

99.1 Press Release Dated October 26, 2010

4